Sign in Subscribe
Scientists

Genetic Variations Linked to Prostate Cancer Risk in Study Published in Carcinogenesis

Strategic Insights

— 1 min read

Recent research published in the journal Carcinogenesis investigates the relationship between genetic variations in estrogen-related genes and the risk of prostate cancer. Using data from the Prostate Cancer Prevention Trial (PCPT), the researchers found associations between specific polymorphisms in the CYP19A1 and UGT1A1 genes and the risk of prostate cancer. The study suggests that genetic variations in these genes may play a role in the development of prostate cancer, particularly among men not receiving finasteride treatment.

Key Takeaways:

  • The study found a significant association between the CYP19A1 7/8 genotype and an increased risk of prostate cancer in men not receiving finasteride treatment (OR = 1.70, 95% CI = 1.16-2.5).
  • The researchers also found an association between the heterozygous short (7 repeats) genotype of the UGT1A1 gene and an increased risk of low-grade prostate cancer (OR = 1.34, 95% CI = 1.05-1.70).
  • The study's results indicate that genetic variations in estrogen metabolism genes may influence prostate cancer risk, but their effects may be modified by factors altering hormone metabolism, such as finasteride treatment.
  • The associations observed in the study were not found among men in the finasteride arm.
  • The study suggests that understanding genetic variations in estrogen metabolism genes may provide new insights into the development of prostate cancer.

Statistics:

  • 1154 cases and 1351 controls were included in the study.
  • The study used logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (95% CIs) separately in the placebo and finasteride arms.
  • The CYP19A1 7/8 genotype was associated with a 50% increase in the risk of prostate cancer (OR = 1.70, 95% CI = 1.16-2.5).
  • The UGT1A1 (TA)(n) repeat polymorphism was associated with a 34% increase in the risk of low-grade prostate cancer (OR = 1.34, 95% CI = 1.05-1.70).

Sources:

  • Tang, L., et al. (2011). Repeat polymorphisms in estrogen metabolism genes and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Carcinogenesis, 32(10), 1500-1506.
  • University of Texas Health Science Center San Antonio, Dept. of Urology, San Antonio, TX 78229, United States.
  • Oxford University Press, Great Clarendon St., Oxford OX2 6DP, England.

Read more